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Abstract
Potential deleterious effects of cardiopulmonary bypass (CPB) and
cardioplegic cardiac arrest are known to influence outcome. The
inflammatory response after CPB may have unfavourable effects
especially in high-risk patients, for example, the very elderly. Thus,
to blunt the release of pro-inflammatory mediators seems to be a
promising approach. So far, numerous attempts at immune
modulation have been performed. However, the management of
cardiac surgery patients needs further improvement. In this context,
Gombocz and colleagues investigated the potential anti-
inflammatory effect of dextran-70. Their results suggest that
compared to gelatine, dextran-70 reduces the inflammatory
response in patients after CPB.
Gombocz and colleagues performed a prospective, random-
ized, double blind study in 40 patients undergoing cardio-
pulmonary bypass (CPB). They investigated the anti-inflam-
matory potential of dextran-70 to modulate systemic
inflammatory response syndrome (SIRS) and myocardial
ischemia/reperfusion (I/R) injury following cardiac operations.
Interestingly, they could demonstrate that the infusion of
dextran-70 before and after CPB reduces inflammation and
cardiac troponin I release [1].
The potential deleterious effects of coronary artery bypass
grafting (CABG) are well investigated under various condi-
tions including CPB and off-pump coronary artery bypass
(OPCAB). There are several underlying mechanisms behind
the unfavourable effects of CPB. This includes the systemic
inflammation response induced by contact between immune
competent cells and the extracorporal circuit, the ischemia-
reperfusion injury of several organs, and the potential
endotoxemia after splanchnic hypoperfusion and consecutive
damage of the mucosal barrier [2]. It is well known that in
low-risk patients the inflammatory response after CPB is less
pronounced [3]. Avoiding CPB might improve the outcome
even in elderly patients with higher morbidity [4] and might
lead to good long-term results [5].
Nevertheless, the use of CPB is an essential requirement in
certain cardiac surgery patients and routinely performed in
cardiac surgery. The inflammatory response to CPB is
accompanied by an increase in body temperature, leucocy-
tosis and tissue oedema [2] as well as an increased release
of cytokines such as interleukin-6 (IL-6) and IL-10 [6]. This
was the rationale for investigations of immune modulation by
corticosteroids [7], cyclooxygenase inhibitors [8], comple-
ment directed therapies [9], and adhesion molecule blockade
[10]. The need for further studies was demonstrated by new
insights regarding the therapy with aprotinin. Recently, it was
shown that this widely used drug in cardiac surgery is
associated with an increased risk of death even in long-term
follow up after five years [11].
Gene array analysis revealed that leukocytes overexpress
adhesion and signalling proteins after CPB which may lead to
succeeding tissue inflammation [12]. Modulation of the
inflammatory response seems to be an interesting therapeutic
approach.
Previously, an anti-inflammatory effect of dextran could be
demonstrated in experimental settings. Steinbauer and
colleagues showed in ischemia-reperfusion injury in striated
muscle, using intravital microscopy, that dextran attenuates
postischemic leukocyte rolling in a molecular weight
dependent manner [13].
In this context, the study by Gombocz and colleagues [1]
yields interesting aspects on the immune modulation by
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dextran-70 in patients undergoing CABG. Using dextran-70
infusion in the early post-CPB phase is associated with lower
inflammation when compared to gelatine. After 24 hours
procalcitonin as well as cardiac troponin I and soluble
adhesion molecules were found to be lower using dextran-70
[1]. Thus, this study suggests that compared to gelatine,
dextran-70 reduces the inflammatory response in patients
after CPB.
Some limitations of the study by Gombocz and colleagues
need to be addressed: the single centre design including a
small number of patients and a short observation period of
approximately two days [1]. Nevertheless, the authors
succeeded to further the exciting area of peri-operative
inflammation in cardiac surgery.
As so often, further investigations are warranted to evaluate
the effects of dextran-70 treatment in cardiac surgery. These
trials need to be limited to high-risk patients most likely to
experience benefit by anti-inflammatory therapies. Addition-
ally, a combination of plasma inflammatory mediators and
gene array analysis may lead to the identification of patients
being more susceptible to harmful effects of CPB.
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